ArticleInflammopharmacology2026
Preparation of bacoside A encapsulated PLGA-PEG nanoparticles for neuroprotection against kainic acid-induced excitotoxicity.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The inherent challenges posed by the blood-brain barrier (BBB) complicate the effective delivery of neuroprotective drugs. In response to these limitations, plant-based nanoparticle formulations are gaining interest for enhancing patient outcomes while minimizing side effects. Bacoside A (BM3) is a nootropic and neuroprotective saponin found in Bacopa monnieri. Owing to its limited permeability across the blood-brain barrier, BM3 is encapsulated within polymeric nanoparticles (NPs) for effective delivery. This study investigates the effects of BM3 encapsulated PLGA-PEG nanoparticles (BM3NPs) on kainic acid (KA)-induced excitotoxicity in a mouse model. It evaluates the protective effects of BM3NPs against neuroinflammation, oxidative stress, overexpression of seizure markers, and dysregulation of the mTOR pathway. BM3NPs exhibited an optimal size of 165.5 nm and a zeta potential of - 32.5 mV, ensuring effective drug delivery. TEM studies demonstrated that BM3NPs (4 mg/kg, b.w.) reduced KA-induced brain tissue damage by restoring normal nuclear outline and strengthening brain membrane integrity. BM3NP also suppressed the overexpression of fractalkine, AMPA glutamate receptors and mTORC1 signaling. BM3NP treatment also led to an increase in antioxidant levels while reducing the expression of proinflammatory cytokines. Overall, the findings suggest that BM3NPs could serve as a promising therapeutic option for addressing KA-induced excitotoxicity.
Indexed as
Identifiers
42432343What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.